SCHEMBL6891790

SCHEMBL6891790

O=C(OCI)Oc1ccc2c(c1)CCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
RXRB P28702 4/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
RXRA P19793 3/20 0.46
RXRG P48443 3/20 0.46
MAPT P10636 3/20 0.45
POLB P06746 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TP53 P04637 1/20 0.43
GFER P55789 1/20 0.43
PAX8 Q06710 1/20 0.43
KLF5 Q13887 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.43
PPARG P37231 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11653596 0.85 SMN1; SMN2 (0.58) SMN1; SMN2ALOX15TSHRHSD17B10RXRB
SCHEMBL6891449 0.84 POLB (0.50) SMN1; SMN2ALOX15TSHRHSD17B10RXRB
SCHEMBL442937 0.84 SMN1; SMN2 (0.49) SMN1; SMN2ALOX15TSHRHSD17B10RXRB
SCHEMBL6892407 0.82 MAPT (0.49) SMN1; SMN2ALOX15TSHRHSD17B10RXRB
SCHEMBL9719992 0.81 ALOX15 (0.59) SMN1; SMN2ALOX15TSHRHSD17B10RXRB
SCHEMBL6890990 0.80 SMN1; SMN2 (0.54) SMN1; SMN2ALOX15TSHRHSD17B10RXRB
SCHEMBL6890994 0.79 POLB (0.54) SMN1; SMN2ALOX15TSHRHSD17B10NPC1
SCHEMBL6887121 0.79 ALOX15 (0.47) SMN1; SMN2ALOX15TSHRHSD17B10RXRB
SCHEMBL17087126 0.78 SMN1; SMN2 (0.55) SMN1; SMN2ALOX15TSHRHSD17B10RXRB
SCHEMBL875632 0.76 ALOX15 (0.57) SMN1; SMN2ALOX15TSHRHSD17B10RXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 SMN1; SMN2 2954/4885ALOX15 2514/4885TSHR 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.